Patent details

EP2691097 Title: COMPOSITIONS COMPRISING NALTREXONE FOR USE IN TREATING SCLERODERMA

Basic Information

Publication number:
EP2691097
PCT Application Number:
TR2011000075
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP117209015
PCT Publication Number:
WO2012134410
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
COMPOSITIONS COMPRISING NALTREXONE FOR USE IN TREATING SCLERODERMA
French Title of Invention:
COMPOSITIONS COMPRENANT DE LA NALTREXONE POUR UTILISATION DANS LE TRAITEMENT DE LA SCLÉRODERMIE
German Title of Invention:
ZUBEREITUNGEN ENTHALTEND NALTREXON ZUR VERWENDUNG BEI DER BEHANDLUNG VON SKLERODERMIE
SPC Number:

Dates

Filing date:
31/03/2011
Grant date:
20/12/2017
EP Publication Date:
05/02/2014
PCT Publication Date:
04/10/2012
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
20/12/2017
EP B1 Publication Date:
20/12/2017
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
31/03/2018
Expiration date:
31/03/2031
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
13/12/2017
 
 

Name:
Imuneks Farma Ilaç Sanayi Ve Ticaret A.S.
Address:
Pak is Merkezi Prof. Dr. Bülent Tarcan Sok. No: 5/1 Gayrettepe, 34349 Istanbul, Türkiye (TR)

Inventor

1

Name:
PISAK, Mehmet
Address:
Türkiye (TR)

2

Name:
SELAMOGLU, Mehmet Levent
Address:
Türkiye (TR)

3

Name:
PISAK, Ibrahim Mustafa Iskender
Address:
Türkiye (TR)

4

Name:
BINGOL, Semra
Address:
Türkiye (TR)

Classification

IPC classification:
A61K 9/00; A61K 9/06; A61K 9/48; A61K 31/485; A61P 43/00;

Publication

European Patent Bulletin

Issue number:
201751
Publication date:
20/12/2017
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
31/07/2018 Outgoing Correspondence 1